Research Summary

Selected Publications

• 1. Okada M, Yamasaki S, Nakazato H, Hirahara Y, Ishibashi T, Kawamura M, Shimizu K, Fujii S^*.:
  "ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy."
  Cancer Research. 84(17):2792-2805 (2024)
• 2. Shimizu K, Ueda S, Kawamura M, Aoshima H, Satoh M, Nakabayashi J, Fujii S^*.:
  "Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8+T cells against tumor."
  J Immunother Cancer. 11(7):e006409 (2023)
• 3. Fujii S^*, Kawamata T, Shimizu K, Nakabayashi J, Yamasaki S, Iyoda T, Shinga J, Nakazato H, Sanpei A, Kawamura M, Ueda S, Dörrie J, Mojsov S, Dhodapkar MV, Hidaka M, Nojima M, Nagamura F, Yoshida S, Goto T, Tojo A.:
  "Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML."
  Molecular Therapy Oncolytics. 27:315-332 (2022)
• 4. Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, and Fujii S^*.:
  "Systemic DC activation modulates the tumor microenvironment and shapes the long-lived tumor-specific memory mediated by CD8+ T cells."
  Cancer Res. 76:3756-66 (2016)
• 5. Shimizu K, Sato Y, Shinga J, Watanabe T, Endo T, Asakura M, Yamasaki S, Kawahara K, Kinjo Y, Kitamura H, Watarai H, Ishii Y, Tsuji M, Taniguchi M, Ohara O, Fujii S^*.:
  "KLRG+ invariant natural killer T cells are long-lived effectors."
  Proc Natl Acad Sci U S A. 111:12474-9 (2014)
• 6. Fujii S^*, Goto A, Shimizu K.:
  "Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity."
  Blood. 113:4262-72 (2009)
• 7. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S^*.:
  "Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells."
  J Exp Med. 204: 2641-53 (2007)
• 8. Fujii S, Liu K, Smith C, Bonito AJ, and Steinman RM.:
  "The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation."
  J Exp Med. 199: 1607-1618 (2004)
• 9. Fujii S, Shimizu K, Smith C, Bonifaz L, and Steinman RM.:
  "Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein."
  J Exp Med. 198: 267-279 (2003)
• 10. Fujii S, Shimizu K, Kronenberg M and Steinman R.M.:
  "Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs."
  Nat Immunol. 3:867-874 (2002)

Recent Research Results

• 

  Dec. 28, 2021
  Immune response to seasonal coronaviruses may offer protection against COVID-19

• 

  Jul. 1, 2016
  New anti-cancer strategy mobilizes both innate and adaptive immune response

• 

  Jan. 23, 2015
  Expanding the immune system’s memory

• 

  Apr. 26, 2013
  Giving antitumor immunity a helping hand

Related Links

Lab Members

Contact Information

1-7-22 Suehiro-cho, Tsurumi-ku,
Yokohama City, Kanagawa,
230-0045, Japan
Tel: +81-(0)45-503-7062
Fax: +81-(0)45-503-7061
Email: shin-ichiro.fujii＠riken.jp